NextCure NXTC 深 沪
等待开盘 11-11 09:30:00 美东时间
8.4999
-0.460
-5.14%
华盛通- 最 高9.16
- 今 开8.84
- 成交量 2.07万股
- 最 低 8.4083
- 昨 收 8.96
- 总市值 2277.80万
- 52周最高 16.80
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 2.688
- 委 比 -98.02%
- 总股本 267.98万
- 历史最高 1308.00
- 量 比 1.18
- 振 幅 8.39%
- 历史最低 2.688
- 每 手 1
- 风险率 3.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Ladenburg Thalmann Upgrades NextCure to Buy, Announces $18 Price Target
Ladenburg Thalmann analyst Kevin DeGeeter upgrades NextCure (NASDAQ:NXTC) from Neutral to Buy and announces $18 price target.
11-07 20:49
NextCure Q3 EPS $(3.22) Beats $(3.98) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(3.22) per share which beat the analyst consensus estimate of $(3.98) by 19.16 percent. This is a 34.95 percent increase over losses of $(4.95) per share from the same
11-06 05:52
先声再明新型ADC候选药物SIM0505完成Ⅰ期临床美国首例患者入组
•首例美国患者已完成给药，已有剂量组已观察到多重应答； • 多区域试验将加速概念验证，预计于2026年上半年获得数据。 中国上海/美国马里兰州贝尔茨...
10-16 21:14
NextCure Doses First U.S. Patient With SIM0505 In Global Phase 1 Cancer Trial; Targets Proof-Of-Concept Data By 1H 2026
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE
10-16 20:09
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
NextCure and Simcere Zaiming announce the dosing of the first U.S. patient in the Phase 1 trial of SIM0505, a CDH6-targeted ADC, at a mid-tier dose level. The multi-regional trial aims to accelerate proof-of-concept data by mid-2026. SIM0505 has shown promising safety and tolerability, with enrollment expanding in the U.S. while dose escalation continues in China. Both companies highlight the potential of SIM0505 to become a leading ADC for CDH6 ...
10-16 12:05
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NextCure, Inc. will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 4:00 pm ET in New York City. A live audio webcast will be available on the company’s website, www.nextcure.com, with a replay archived for 30 days. NextCure focuses on developing innovative cancer therapies, including antibody-drug conjugates, targeting patients who do not respond to current treatments. For m...
09-04 11:00
